Danica Pension Livsforsikringsaktieselskab Makes New $53.77 Million Investment in Eli Lilly and Company $LLY

Danica Pension Livsforsikringsaktieselskab purchased a new stake in shares of Eli Lilly and Company (NYSE:LLY) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 58,464 shares of the company’s stock, valued at approximately $53,773,000. Eli Lilly and Company accounts for 1.0% of Danica Pension Livsforsikringsaktieselskab’s holdings, making the stock its 22nd largest position.

A number of other institutional investors and hedge funds have also recently modified their holdings of LLY. Norges Bank purchased a new stake in Eli Lilly and Company during the 4th quarter valued at about $12,976,634,000. J. Stern & Co. LLP increased its stake in Eli Lilly and Company by 46,191.3% in the 4th quarter. J. Stern & Co. LLP now owns 4,047,245 shares of the company’s stock worth $4,047,245,000 after purchasing an additional 4,038,502 shares during the period. Cardano Risk Management B.V. increased its stake in Eli Lilly and Company by 876.1% in the 4th quarter. Cardano Risk Management B.V. now owns 2,375,050 shares of the company’s stock worth $2,552,419,000 after purchasing an additional 2,131,734 shares during the period. Fifth Third Bancorp lifted its position in Eli Lilly and Company by 321.3% in the first quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company’s stock valued at $1,805,959,000 after purchasing an additional 1,497,423 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in Eli Lilly and Company by 10.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,910,505 shares of the company’s stock valued at $16,024,022,000 after purchasing an additional 1,432,069 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Price Performance

LLY opened at $1,175.15 on Wednesday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,249.45. The stock has a market capitalization of $1.11 trillion, a PE ratio of 41.75, a price-to-earnings-growth ratio of 1.44 and a beta of 0.51. The stock’s 50 day moving average price is $1,126.19 and its 200-day moving average price is $1,037.68.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm’s revenue was up 55.5% on a year-over-year basis. During the same quarter last year, the firm posted $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities research analysts predict that Eli Lilly and Company will post 34.55 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 24.58%.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Several market commentary pieces highlighted Lilly’s leadership in GLP-1 obesity treatments, its expanding pipeline, and the view that its growth outlook remains strong despite intensifying competition from Novo Nordisk.
• Positive Sentiment: Analyst-focused coverage continued to point to Lilly’s momentum from Zepbound and Mounjaro, with investors still treating the company as a core winner in the fast-growing weight-loss and diabetes market.
• Positive Sentiment: Broader healthcare stocks also moved higher, which likely provided a supportive backdrop for Eli Lilly shares during the session.
• Neutral Sentiment: Eli Lilly defended its advertising, saying its comparisons are based on the SURMOUNT-5 trial, while noting Novo’s criticism centers on the use of older dose comparisons rather than direct head-to-head data.
• Negative Sentiment: Novo Nordisk sued Eli Lilly in U.S. federal court, accusing the company of false and misleading advertising for Zepbound and Mounjaro and seeking to stop the ads, force corrective marketing, and recover damages. Reuters article about the lawsuit

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on LLY shares. Truist Financial raised their target price on shares of Eli Lilly and Company from $1,281.00 to $1,370.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. Royal Bank Of Canada upped their price target on shares of Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the company an “outperform” rating in a report on Wednesday, July 8th. Barclays increased their price target on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an “overweight” rating in a research report on Monday, May 4th. UBS Group boosted their price objective on shares of Eli Lilly and Company from $1,250.00 to $1,425.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Finally, Weiss Ratings raised shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, July 1st. Two analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average target price of $1,283.64.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.